Allergy and Asthma Center Welcomes Ryan B. Israelsen, M.D.

August 8, 2018

The Allergy and Asthma Center is excited to announce the addition of Ryan B. Israelsen, M.D. to our group. Dr. Israelsen joins us from the University of Colorado Allergy and Immunology Fellowship based at Denver Children’s Hospital. He previously completed a combined Internal Medicine/Pediatrics residency at the University of Pittsburgh Medical Center and medical school at the University of Utah. Dr. Israelsen’s research interest has focused on food allergy and clinic-based oral food challenges. He will be a key addition to our group as we serve Southern Oregon and Northern California communities. Dr. Irsraelsen is accepting pediatric and adult patients starting July 2018. We welcome Ryan, McKenzie and their 4 children to...

Read More

AUVI-Q RECALL

October 29, 2015

Sanofi US has issued a recall of all Auvi-Q devices. http://www.news.sanofi.us/2015-10-28-Sanofi-US-Issues-Voluntary-Nationwide-Recall-of-Auvi-Q-Due-to-Potential-Inaccurate-Dosage-Delivery AAC dose not prescribe epinephrine “Dispense As Written”, so pharmacies can switch to a different self-injectable epinephrine device based on patient preference (or, as in this case, due to a recall). Information regarding reimbursement for out of pocket cost to replace Auvi-Q devices is available on the Sanofi US site (see above).

Read More

MAY 2014 UPDATE ON SUB-LINGUAL IMMUNOTHERAPY (SLIT)

May 16, 2014

The FDA has recently approved 3 products for use as SLIT in the US market. 2 products treat grass pollen allergy: Oralair (Stallergenes/Greer) and Grastek (ALK/Merck). 1 product treats ragweed allergy: Ragwitek (Merck). As mentioned in the last AAC blog post, SLIT for grass is relevant in the Rogue Valley whereas SLIT for ragweed is not (based on our local aerobiology). Treatment for grass pollen allergy with SLIT is best accomplished by beginning treatment at least 3 months prior to the onset of grass season. We typically see grass pollen on the Rotorod sampler at our Medford office in early...

Read More

FDA ADVISORY COMMITTEE SUBLINGUAL IMMUNOTHERAPY RECOMMENDATIONS

February 14, 2014

Subcutaneous immuntherapy (SCIT or “allergy shots”) has been utilized for decades as a safe and effective treatment for allergic asthma, allergic rhinitis, hymenoptera hypersensitivity, and allergic conjunctivitis. Multiple well designed trials have demonstrated that SCIT is a disease-modifying treatment for allergies and asthma with reduction in medication use, lower symptom frequency and severity, reduction in exacerbation rates, less development of new allergies, and improvement in lung function and quality of life. Financial analyses have documented cost effectiveness, with reduction in overall healthcare utilization for appropriately diagnosed and treated SCIT patients; which has led to widespread coverage by all major payers...

Read More

BEAUTIFUL AEROBIOLOGY… THIS IS WHAT WE ARE SEEING UNDER THE MICROSCOPE IN MEDFORD: TREE POLLEN. HAPPY SPRING!

March 28, 2013
Read More

SUMMER CAMP FOR CHILDREN WITH FOOD ALLERGIES

March 19, 2013

Camp Blue Spruce announcement

Read More